How AI Is Becoming Foundational to Biopharma Strategy, R&D, and Risk Management The 2026 JP Morgan Healthcare Conference made one theme unmistakably clear: AI has moved from experimental to existential for healthcare and life sciences organizations. Across pharma, biotech, health systems, and technology companies, leaders emphasized that AI is no longer a peripheral innovation—it is quickly becoming core infrastructure for competitive advantage, operational resilience, and scientific discovery. While generative AI commanded attention in 2024 and 2025, this year’s conversations demonstrated a deeper shift: organizations are now building enterprise-wide systems, partnerships, and capital investments that position AI as a long-term strategic capability rather than a near-term pilot. Below, Altum distills the most important developments from JPM and outlines what leaders should take away as AI becomes a defining force in biopharma strategy. AI Becomes Foundational Infrastructure—Not a Side Experiment A defining moment of the conference was the announcement of a $1 billion co-innovation AI lab between NVIDIA and Eli Lilly, designed to accelerate lab automation, drug discovery, and clinical development. This is one of the largest AI‑in‑pharma investments to date and signals three important shifts: AI is moving upstream. Drug discovery, molecular design, and early research are now priority AI use […]

Understand the intricacies of MedTech product development risk highlighted at the J.P. Morgan Healthcare Conference.

Part of In Preparation’s coverage of the 2026 J.P.

Generation of 120M+ cells and 225,000 perturbation interactions will accelerate virtual cell model development.

2.8k words, 13 minutes reading time

The Advanced Research Projects Agency for Health (ARPA-H) supports transformative research to drive biomedical and health breakthroughs ranging from molecular to societal to provide transformative hea...